Aridis Pharmaceuticals Inc. with ticker code (ARDS) now have 5 analysts in total covering the stock. The consensus rating is ‘Buy’. The target price ranges between 22 and 11 calculating the average target price we see 17.2. Now with the previous closing price of 7.25 this would indicate that there is a potential upside of 137.2%. The day 50 moving average is 6.7 and the 200 moving average now moves to 6.97. The company has a market capitalisation of $73m. You can visit the company’s website by visiting: http://www.aridispharma.com
Aridis Pharmaceuticals, a late-stage biopharmaceutical company, focuses on the discovery and development of targeted immunotherapy using fully human monoclonal antibodies (mAb) to treat life-threatening infections. Its lead product candidate is AR-301, a fully human mAb of immunoglobulin 1 (IgG1) that is in Phase III pivotal trials for the treatment of lung infections resulting from S. aureus alphatoxin. The company is also developing AR-105, a fully human IgG1 mAb, which is in Phase II trials to target gram-negative bacteria P. aeruginosa; AR-101, a human IgM mAb, which is in Phase II clinical trials for the treatment of hospital-acquired pneumonia (HAP)and ventilator-associated pneumonia (VAP) caused by P. aeruginosa serotype O11; AR-401 that is in preclinical stage to treat infections caused by Acinetobacter baumannii; AR-201, a fully human IgG1 mAb preclinical program for respiratory syncytial virus; and AR-501, an anti-infective therapy, which is in Phase I/IIa clinical trial to manage chronic lung infections in cystic fibrosis patients and acute pneumonia in HAP and VAP patients. Aridis Pharmaceuticals was founded in 2003 and is headquartered in San Jose, California.